2 days ago
7
Soumya Eswaran
Tue, December 16, 2025 astatine 9:25 AM CST 3 min read
Riverwater Partners, an concern absorption company, released its “Micro Opportunities Strategy” Q3 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The strategy reported coagulated implicit returns successful the 4th but lagged the benchmark arsenic it did not support gait with the beardown rally. The strategy continues to absorption connected prime companies successful the volatile environment. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.
In its third-quarter 2025 capitalist letter, Riverwater Partners Micro Opportunities Strategy highlighted stocks specified arsenic Delcath Systems, Inc. (NASDAQ:DCTH). Delcath Systems, Inc. (NASDAQ:DCTH) is an interventional oncology company. The one-month instrumentality for Delcath Systems, Inc. (NASDAQ:DCTH) was 15.14%, and its shares mislaid 16.58% implicit the past 52 weeks. On December 15, 2025, Delcath Systems, Inc. (NASDAQ:DCTH) banal closed astatine $10.08 per share, with a marketplace capitalization of $352.961 million.
Riverwater Partners Micro Opportunities Strategy stated the pursuing regarding Delcath Systems, Inc. (NASDAQ:DCTH) successful its 3rd 4th 2025 capitalist letter:
"Delcath Systems, Inc. (NASDAQ:DCTH) is simply a commercial-stage oncology institution focused connected liver-directed crab therapies. Its proprietary Hepzato Kit delivers high-dose chemotherapy straight to the liver portion minimizing systemic exposure, allowing for targeted attraction of metastatic cancers that chiefly impact the liver. The therapy is presently approved for ocular melanoma with liver metastases, with ongoing trials specified arsenic CHOPIN including first-line use, and exploring its imaginable successful broader indications.
English (CA) · 
English (US) · 
Spanish (MX) ·